ADMA BIOLOGICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ADMA BIOLOGICS, INC. (ADMA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.15M, a 2772.50% increase year-over-year.
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $162.00K, a 83.55% decline year-over-year.
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $701.00K, a 156.78% increase year-over-year.
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$1.02M, a 515.51% decline year-over-year.
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $708.00K, a 2.34% decline from fiscal 2024.
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $725.00K, a 743.02% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $86.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.31M 10-Q · filed 2026-08-05 | $2.01M derived: sum of 3 quarters · filed 2026-08-05 | $994.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $162.00K 10-Q · filed 2026-05-06 | $863.00K derived: sum of 2 quarters · filed 2026-05-06 | -$155.00K derived: sum of 3 quarters · filed 2026-05-06 | -$115.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$317.00K derived: sum of 2 quarters · filed 2026-02-25 | -$277.00K derived: sum of 3 quarters · filed 2026-08-05 | $708.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$978.00K derived: sum of 2 quarters · filed 2026-08-05 | $7.00K 10-Q · filed 2025-11-05 | $280.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.02M 10-Q · filed 2026-08-05 | $1.30M derived: sum of 3 quarters · filed 2026-08-05 | $1.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $985.00K 10-Q · filed 2026-05-06 | $1.26M derived: sum of 2 quarters · filed 2026-05-06 | $1.50M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $518.00K derived: sum of 2 quarters · filed 2026-02-25 | $725.00K 10-K · filed 2026-02-25 | |
| 2024-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $452.00K 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $207.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $86.00K 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |